• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Cel-Sci Corporation

    12/30/24 4:16:28 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CVM alert in real time by email
    NT 10-K 1 cvm_nt10k.htm NT 10-K cvm_nt10k.htm

     

    U.S. SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SEC File Number 001-11889

    CUSIP Number 150837508

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check One):

     

    ☒

    Form 10-K

    ☐

    Form 20-F 

    ☐ 

    Form 11-K 

    ☐ 

    Form 10-Q

    ☐

    Form 10-D

    ☐

    Form N-SAR

     

    For Period Ended: September 30, 2024.

     

     

    ☐

    Transition Report on Form 10-K

     

     

     

     

    ☐

    Transition Report on Form 10-Q

     

     

     

     

    For the Transition Period Ended: ________________________________

     

    Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.

     

    ________________________________

     

    Part I - Registrant Information

    ________________________________

     

    Full Name of Registrant: CEL-SCI CORPORATION

     

    Former Name if Applicable: N/A

     

    Address of Principal Executive Office (Street and Number)

     

    8229 Boone Blvd. #802

     

    City, State and Zip Code

     

    Vienna, VA 22182

     

     

     

     

    _________________________________

     

    Part II - Rules 12b-25(b) and (c)

    _________________________________

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    ☒

    (a)

    The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

     

     

     

    ☒

    (b)

    The subject annual report, semi-annual report, or transition report or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form l0-Q or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

     

     

     

    ☐

    (c)

    The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

    _________________________________

     

    Part III - Narrative

    _________________________________

     

    State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K, 10-Q, or N-SAR, or the transition report or portion thereof could not be filed within the prescribed time period.

     

    The Company did not complete its financial statements for the year ended September 30, 2024 in sufficient time to allow the filing of the 10-K report by December 30, 2024.

     

     
    2

     

     

    _________________________________

     

    Part IV - Other Information

    _________________________________

     

     

    (1)

    Name and telephone number of person to contact in regard to this notification

     

     

    William T. Hart

     

    (303)

     

    839-0061

     

    (Name)

     

    (Area Code)

     

    (Telephone Number)

     

     

    (2)

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding l2 months (or for such shorter period that the registrant was required to file such reports) been filed? If answer is no, identify report(s). ☒ Yes      ☐ No

     

     

     

     

    (3)

     Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes      ☒ No

     

     

     

     

     

    If so:  attach an explanation of the   anticipated change, both narratively and  quantitatively, and, if appropriate, state    the reasons why a reasonable estimate of  the results cannot be made.

     

     
    3

     

     

    CEL-SCI CORPORATION

    (Name of Registrant as specified in charter)

     

    has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Date: December 30, 2024

    By:

    /s/Geert Kersten

     

     

     

    Geert Kersten

     

     

     

    Chief Executive Officer

     

     

    ATTENTION

     

    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     
    4

     

    Get the next $CVM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Watson Robert Eugene bought $27,800 worth of shares (20,000 units at $1.39), increasing direct ownership by 451% to 24,431 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      5/10/24 9:04:18 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Prichep Patricia B bought $11,120 worth of shares (8,000 units at $1.39), increasing direct ownership by 4% to 232,326 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      5/9/24 1:07:10 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kersten Geert R bought $41,700 worth of shares (30,000 units at $1.39), increasing direct ownership by 3% to 1,195,309 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      5/9/24 9:19:04 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CVM
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Cel-Sci Corporation

      DEF 14A - CEL SCI CORP (0000725363) (Filer)

      4/9/25 12:59:47 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Cel-Sci Corporation

      PRE 14A - CEL SCI CORP (0000725363) (Filer)

      3/21/25 5:15:11 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cel-Sci Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - CEL SCI CORP (0000725363) (Filer)

      3/18/25 5:07:52 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CVM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

      Concluded a successful meeting with Saudi Food and Drug Authority CEL-SCI was encouraged to apply for Conditional Approval with Breakthrough Therapy Designation based on data from its concluded Phase 3 study Evaluating Saudi Arabia-based partnerships to potentially fund local manufacturing and launch Multikine throughout the region CEL-SCI Corporation (NYSE:CVM) today announced that it met with the Saudi Food and Drug Authority (SFDA) to discuss the development of Multikine cancer immunotherapy* (Leukocyte Interleukin, Injection), the vast amount of Multikine data available to support a marketing application for its use as a treatment of head and neck cancer, and the possible pathway

      4/23/25 8:30:00 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

      Head and neck cancer patients treated with Multikine who had complete or partial tumor responses before surgery had improvements in overall survival, suggesting pre-surgical tumor response is a strong indicator of efficacy and leads to improved overall survival A third-party head and neck cancer study published in "Cancer Cell" confirms the observation that pre-surgical tumor responses in head and neck cancer leads to improved survival CEL-SCI Corporation (NYSE:CVM) today announced that a study titled "Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies" by Li Housaiyin et. al., Cancer Cell (2025) provides support for CEL-SCI's approach aimed at see

      4/8/25 9:51:00 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

      Data published in peer-reviewed scientific journal Pathology and Oncology Research Quality of life improvements included reduction in or cessation of pain in the head and neck area, improvement or complete restoration in ability to eat, drink, and swallow, ability for selfcare including walking and using the toilet, and improved emotional wellbeing Complete responders to Multikine treatment reported a 100% (wherein all respondents scored the highest possible improvement from baseline) on 60% (39/65) quality of life measures 89.4% of partial responders to Multikine reported improved quality of life measures Multikine is headed into a final confirmatory Registration Study in head and neck

      3/24/25 9:00:00 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CVM
    Leadership Updates

    Live Leadership Updates

    See more
    • CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

      CEL-SCI Corporation (NYSE:CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815767286/en/The table includes detailed results from the bias analysis. (Graphic: Business Wire) Clinical and Corporate Developments include: In July 2024, following the end of the third fiscal quarter, CEL-SCI reported the results of a bias analysis. The bias analysis, a standard process to ensure a trial's findings are reliable, was conducted in preparation for CEL-SCI's upcoming confirmatory Registration Study. This

      8/15/24 8:00:00 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEL-SCI Appoints Robert Watson as Chairperson of the Board

      CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to drive an efficient capital structure. During his career as CEO or President of private and publicly traded companies in the healthcare sector, Bob negotiated over a half dozen exits and more than $750 million in capital transactions including IPOs, secondary offerings, and debt in

      7/8/24 9:15:00 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEL-SCI Appoints Mario Gobbo to Its Board of Directors

      CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory services. He has served as an officer or director for a number of companies including several biotech companies: Xcovery, Ocimum/Genelogic and Helix BioPharma. Prior to that, Mr. Gobbo worked in the financial industry for Lazard LLC, Swiss Bank Corporation, the European Bank for Reconstruction and Development, Natixis Bleichroeder, Inc., and International Finance Corporation

      4/23/24 9:00:00 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

      SC 13G/A - CEL SCI CORP (0000725363) (Subject)

      2/8/23 10:48:28 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

      SC 13G/A - CEL SCI CORP (0000725363) (Subject)

      4/11/22 1:55:14 PM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

      SC 13G/A - CEL SCI CORP (0000725363) (Subject)

      2/11/22 7:53:04 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Talor Eyal was granted 10,416 shares, increasing direct ownership by 8% to 135,013 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      4/1/25 9:51:43 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Prichep Patricia B was granted 15,432 shares, increasing direct ownership by 6% to 266,230 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      4/1/25 9:49:33 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Kersten Geert R was granted 22,786 shares, increasing direct ownership by 2% to 1,240,378 units (SEC Form 4)

      4 - CEL SCI CORP (0000725363) (Issuer)

      4/1/25 9:46:47 AM ET
      $CVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care